Rigel Pharmaceuticals Inc.
RIGL Nasdaq
SEC CIK 1034842
Follow Rigel Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$80.9M
+16.5% vs same quarter last year
Net income
$13.2M
−52.7% vs same quarter last year
EPS, diluted
$0.65
−55.5% vs same quarter last year
Operating cash flow
$34.6M
+43.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $294.3M | $367M |
| FY24 | $179.3M | $17.5M |
| FY23 | $116.9M | −$25.1M |
| FY22 | $120.2M | −$58.6M |
| FY21 | $149.2M | −$17.9M |
| FY20 | $108.6M | −$29.7M |
| FY19 | $59.3M | −$66.9M |
| FY18 | $44.5M | −$70.5M |
| FY17 | $4.5M | −$78M |
| FY16 | $20.4M | −$69.2M |
| FY15 | - | −$51.5M |
| FY14 | - | −$90.9M |
| FY13 | - | −$89M |
| FY12 | - | −$98.8M |
| FY11 | - | −$86M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 93.3% | 42.6% | 124.7% |
| FY24 | 89.6% | 13.5% | 9.8% |
| FY23 | 93.9% | −17.5% | −21.5% |
| FY22 | 98.5% | −46.2% | −48.7% |
| FY21 | 99.3% | −8.4% | −12% |
| FY20 | 99.2% | −26.7% | −27.4% |
| FY19 | 98.5% | −116.5% | −112.8% |
| FY18 | 99.4% | −163.3% | −158.3% |
| FY17 | - | −1775.6% | −1739.3% |
| FY16 | - | −342.2% | −339.6% |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | −$74.2M |
| FY21 | $5.3M |
| FY20 | −$53.4M |
| FY19 | −$43M |
| FY18 | −$59.9M |
| FY17 | −$77.7M |
| FY16 | −$76.7M |
| FY15 | −$24M |
| FY14 | −$70.2M |
| FY13 | −$87.3M |
| FY12 | −$88.6M |
| FY11 | −$71.7M |
- Rigel Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Rigel Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 124.7% | −30.6% |
| FY24 | 9.8% | −47% |
| FY23 | −21.5% | −58% |
| FY22 | −48.7% | −80.4% |
| FY21 | −12% | −71.8% |
| FY20 | −27.4% | −62.2% |
| FY19 | −112.8% | −46.2% |
| FY18 | −158.3% | −49.6% |
| FY17 | −1739.3% | −45.9% |
| FY16 | −339.6% | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |